176 related articles for article (PubMed ID: 30835257)
1. Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion.
McEvoy CR; Xu H; Smith K; Etemadmoghadam D; San Leong H; Choong DY; Byrne DJ; Iravani A; Beck S; Mileshkin L; Tothill RW; Bowtell DD; Bates BM; Nastevski V; Browning J; Bell AH; Khoo C; Desai J; Fellowes AP; Fox SB; Prall OW
J Clin Invest; 2019 May; 129(5):1940-1945. PubMed ID: 30835257
[TBL] [Abstract][Full Text] [Related]
2. Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles.
Williams EA; Shah N; Montesion M; Sharaf R; Pavlick DC; Sokol ES; Alexander BM; Venstrom JM; Elvin JA; Ross JS; Tse JY; Mochel MC
Mod Pathol; 2020 Aug; 33(8):1466-1474. PubMed ID: 32123303
[TBL] [Abstract][Full Text] [Related]
3. Clinical response under MEK inhibitor alone in metastatic melanoma with a novel fusion involving the RAF1 gene.
Boileau M; Descarpentries C; Delzenne G; Trentesaux V; Greliak A; Jamme P; Marchetti P; Mortier L
Melanoma Res; 2023 Jun; 33(3):247-251. PubMed ID: 36866640
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
6. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N
Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704
[TBL] [Abstract][Full Text] [Related]
7. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
[TBL] [Abstract][Full Text] [Related]
8. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
9. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
[TBL] [Abstract][Full Text] [Related]
10. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
11. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
12. Novel LRRFIP2-RAF1 fusion identified in an acral melanoma: A review of the literature on melanocytic proliferations with RAF1 fusions and the potential therapeutic implications.
LeBlanc RE; Lefferts JA; Baker ML; Linos KD
J Cutan Pathol; 2020 Dec; 47(12):1181-1186. PubMed ID: 32700768
[TBL] [Abstract][Full Text] [Related]
13. RAF1/BRAF dimerization integrates the signal from RAS to ERK and ROKα.
Varga A; Ehrenreiter K; Aschenbrenner B; Kocieniewski P; Kochanczyk M; Lipniacki T; Baccarini M
Sci Signal; 2017 Mar; 10(469):. PubMed ID: 28270557
[TBL] [Abstract][Full Text] [Related]
14. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
[TBL] [Abstract][Full Text] [Related]
15. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
16. Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
Delzenne G; Boileau M; Jamme P; Farchi O; Mortier L
Melanoma Res; 2024 Apr; 34(2):182-185. PubMed ID: 38329225
[TBL] [Abstract][Full Text] [Related]
17. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.
Palanisamy N; Ateeq B; Kalyana-Sundaram S; Pflueger D; Ramnarayanan K; Shankar S; Han B; Cao Q; Cao X; Suleman K; Kumar-Sinha C; Dhanasekaran SM; Chen YB; Esgueva R; Banerjee S; LaFargue CJ; Siddiqui J; Demichelis F; Moeller P; Bismar TA; Kuefer R; Fullen DR; Johnson TM; Greenson JK; Giordano TJ; Tan P; Tomlins SA; Varambally S; Rubin MA; Maher CA; Chinnaiyan AM
Nat Med; 2010 Jul; 16(7):793-8. PubMed ID: 20526349
[TBL] [Abstract][Full Text] [Related]
18. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma.
Capparelli C; Purwin TJ; Heilman SA; Chervoneva I; McCue PA; Berger AC; Davies MA; Gershenwald JE; Krepler C; Aplin AE
Cancer Res; 2018 Oct; 78(19):5680-5693. PubMed ID: 30115691
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
20. KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth.
Riverso M; Montagnani V; Stecca B
Oncogene; 2017 Jun; 36(23):3322-3333. PubMed ID: 28068326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
